Sign Up for a Free Account
  • Updated 03.13.2021
  • Released 03.01.2004
  • Expires For CME 03.13.2024



Historical note and terminology

Mycophenolate mofetil is the semisynthetic morpholinoethyl ester of mycophenolate acid, which has been developed as an immunosuppressive agent to prevent rejection of transplanted organs. It was commercialized as CellCept by Hoffmann-La Roche. Mycophenolic acid was originally used to treat psoriasis in the 1970s. More recently, this agent has been used to treat several inflammatory conditions, including systemic lupus erythematosus, particularly in lupus nephritis. Currently it is in clinical trials for autoimmune myasthenia gravis, which will be the focus of this article. However, the knowledge of clinical pharmacology and safety of this drug is based on use in transplant patients, the only approved use.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125